BRISBANE, Calif.–(BUSINESS WIRE)– #AHA–Durable efficacy and favorable safety profile supports planned 2027 clinical testing in persistent chylomicronemia.

Subscribe to Our Newsletter

We keep your data private and share your data only with third parties that make this service possible. See our Privacy Policy for more information.